News

Medical Xpress5d
Three-year study of tirzepatide shows that most patients only regain 5% or less from their lowest weight
This post hoc analysis of the SURMOUNT-1 study, at three years, aimed to assess weight regain from nadir weight over three years (36 months / 176 weeks) with tirzepatide treatment. Weight regain ...
News Medical5d
SURMOUNT-1 trial finds tirzepatide supports long term weight control
This post hoc analysis of the SURMOUNT-1 study, at 3 years, aimed to assess weight regain from nadir weight over 3 years (36 months / 176 weeks) with tirzepatide treatment. The original SURMOUNT-1 ...
Gulf News2d
FDA-approved drug offers long-term weight loss in adults without diabetes
The trial uncovered no new safety issues. New Delhi: Taking tirzepatide drug once a week may produce clinically meaningful and sustained weight loss for at least 3 years in adults with overweight ...